U.S. markets closed
  • S&P 500

    4,119.21
    +42.61 (+1.05%)
     
  • Dow 30

    34,092.96
    +6.92 (+0.02%)
     
  • Nasdaq

    11,816.32
    +231.77 (+2.00%)
     
  • Russell 2000

    1,960.81
    +28.87 (+1.49%)
     
  • Crude Oil

    76.70
    -2.17 (-2.75%)
     
  • Gold

    1,966.80
    +21.50 (+1.11%)
     
  • Silver

    24.08
    +0.24 (+1.02%)
     
  • EUR/USD

    1.0995
    +0.0129 (+1.19%)
     
  • 10-Yr Bond

    3.3970
    -0.1320 (-3.74%)
     
  • GBP/USD

    1.2371
    +0.0054 (+0.44%)
     
  • USD/JPY

    128.9070
    -1.1610 (-0.89%)
     
  • BTC-USD

    23,690.62
    +712.88 (+3.10%)
     
  • CMC Crypto 200

    538.70
    +296.03 (+121.98%)
     
  • FTSE 100

    7,761.11
    -10.59 (-0.14%)
     
  • Nikkei 225

    27,346.88
    +19.77 (+0.07%)
     

SpringWorks Therapeutics to Participate in the Evercore ISI 5th Annual HealthCONx Conference

SpringWorks Therapeutics, Inc.
SpringWorks Therapeutics, Inc.

STAMFORD, Conn., Nov. 22, 2022 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced that management will participate in a fireside chat at the Evercore ISI 5th Annual HealthCONx Conference, taking place virtually on Tuesday, November 29, 2022 at 4:20 p.m. ET.

To access the live webcast please visit the Events & Presentations page within the Investors & Media section of the company’s website at https://ir.springworkstx.com. A replay of the webcast will be available on SpringWorks’ website for a limited time following the conference.

About SpringWorks Therapeutics
SpringWorks is a clinical-stage biopharmaceutical company applying a precision medicine approach to acquiring, developing and commercializing life-changing medicines for patients living with severe rare diseases and cancer. SpringWorks has a differentiated targeted oncology pipeline spanning solid tumors and hematological cancers, including two late-stage clinical trials in rare tumor types as well as several programs addressing highly prevalent, genetically defined cancers. SpringWorks’ strategic approach and operational excellence in clinical development have enabled it to rapidly advance its two lead product candidates into late-stage clinical trials while simultaneously entering into multiple shared-value partnerships with innovators in industry and academia to unlock the full potential for its portfolio and create more solutions for patients with cancer. For more information, visit www.springworkstx.com and follow @SpringWorksTx on Twitter and LinkedIn.

Contacts:
Kim Diamond
Vice President, Communications and Investor Relations
Phone: 203-561-1646
Email: kdiamond@springworkstx.com

Samantha Hilson Sandler
Director, Investor Relations
Phone: 203-461-5501
Email: samantha.sandler@springworkstx.com